KAMADA » MEDIA » NEWS

NEWS


Kamada Announces CFO Transition Gil Efron, Deputy CEO and CFO, to Depart Kamada at End of Year; Chaime Orlev to Assume CFO Duties

Press Release / Sep. 18, 2017

Kamada announced that Gil Efron, Deputy Chief Executive Officer (Deputy CEO) & Chief Financial Officer (CFO) recently informed the Company of his plan to leave at the end of the year.

Kamada to Present Corporate Overview at Two Investor Conferences in September

Press Release / Sep. 6, 2017

Kamada announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual Healthcare Conference.

Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action

Press Release / Sep. 6, 2017

Kamada announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with a focus on mechanism of action with BGN Technologies (BGN), the business arm of Ben Gurion University (BGU).  Professor Eli Lewis, Department of Clinical Biochemistry and Pharmacology at BGU, and one of the world’s foremost AAT investigators, will lead the collaboration.

Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection

Press Release / Aug. 25, 2017

"This significant achievement for Kamada represents the second FDA approval for the Company," said Amir London, Kamada's Chief Executive Officer. "We are proud that our unique and advanced immune globulin purification technology was used in the development of KEDRAB, and look forward to a successful launch of the product with Kedrion Biopharma."

Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

Press Release / Aug. 1, 2017

Kamada announced financial results for the three and six months ended June 30, 2017.

Kamada Announces Proposed Public Offering of Ordinary Shares

Press Release / Jul. 28, 2017

Kamada announced that it intends to offer and sell its ordinary shares in an underwritten public offering.

Kamada Announces Pricing of Public Offering of Ordinary Shares

Press Release / Jul. 28, 2017

Kamada announced that it has priced its previously announced underwritten public offering of 3,333,334 of its ordinary shares at a price of $4.50 per share.

Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017

Press Release / Jul. 27, 2017

Kamada Expects to Report Full Financial Results for Second Quarter and Six Months Ended June 30, 2017, and Host Conference Call on August 1, 2017.

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Jul. 20, 2017

Kamada announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).  

out of 139 items.